BridgeBio Oncology Therapeutics, Inc.

Helix Acquisition Corp. II (Nasdaq: HLXB) is a blank-check company in the biotech and pharmaceutical sector that completed its initial public offering in 2023. On March 3, 2025, HLXB announced a business combination with BridgeBio Oncology Therapeutics, Inc., a clinical-stage oncology spinout of BridgeBio Pharma focused on developing precision therapies for genetically defined cancers. That transaction has since closed, bringing BridgeBio Oncology Therapeutics to public markets via the SPAC route. The deal added a targeted-oncology platform to the public biotech landscape at a time of continued investor interest in precision medicine. Sign up for full data on SpacDesk to access complete filing history, deal analytics, and real-time SPAC tracking for HLXB and the broader market.

SPAC Counterparty (1)